Literature DB >> 10906142

Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc.

X Li1, M C Multon, Y Henin, F Schweighoffer, C Venot, J Josef, C Zhou, J LaVecchio, P Stuckert, M Raab, A Mhashilkar, B Tocque, W A Marasco.   

Abstract

The MAPK pathway is required for T-cell activation; however, its role in modulating T-cell function following human immunodeficiency virus type 1 (HIV-1) infection is poorly understood. In this report, we investigated whether Grb3-3, an isoform of the Grb2 (growth factor receptor-bound protein-2) adaptor molecule that is associated with the MAPK pathway, could be involved. We found that Grb3-3, but not its isoform Grb2, is markedly up-regulated in CD4(+) peripheral blood mononuclear cells derived from either in vitro HIV-1-infected cultures or HIV-1-infected human subjects. Analysis of HIV-1 gene products indicated that Tat and Nef, both of which have been implicated in modulating T-cell function, can independently induce expression of Grb3-3. By using NFAT/AP-1, AP-1, or NFAT reporter assays, we found that Grb3-3 can potentiate NFAT (but not AP-1) promoter activity in Jurkat T-cells upon engagement of the T-cell receptor and CD28 co-receptor. In addition, potentiation of NFAT by Grb3-3 is substantially suppressed by MEKK1, a kinase that may play an important role in retaining NFAT in the cytoplasm, and by cyclosporin A. Finally, we also found that Grb3-3 potentiates HIV-1 long terminal (LTR) repeat promoter activity following T-cell receptor stimulation, an effect that can be largely suppressed by cyclosporin A. Taken together, this study indicates that Grb3-3 is a cellular factor that can be up-regulated by HIV-1. In addition, Grb3-3 can also function as a positive factor for T-cell activation and, in doing so, may aid in establishing an intracellular environment that can optimally support HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906142     DOI: 10.1074/jbc.M005535200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Authors:  Françoise Gondois-Rey; Angelique Biancotto; Marcelo Antonio Fernandez; Lise Bettendroffer; Jana Blazkova; Katerina Trejbalova; Marjorie Pion; Ivan Hirsch
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Discovering regulated networks during HIV-1 latency and reactivation.

Authors:  Sourav Bandyopadhyay; Ryan Kelley; Trey Ideker
Journal:  Pac Symp Biocomput       Date:  2006

3.  First evidence of overlaps between HIV-Associated Dementia (HAD) and non-viral neurodegenerative diseases: proteomic analysis of the frontal cortex from HIV+ patients with and without dementia.

Authors:  Li Zhou; Eve Diefenbach; Ben Crossett; Sieu L Tran; Thomas Ng; Helen Rizos; Rejane Rua; Bin Wang; Amit Kapur; Kaushal Gandhi; Bruce J Brew; Nitin K Saksena
Journal:  Mol Neurodegener       Date:  2010-06-24       Impact factor: 14.195

4.  The Grb2 splice variant, Grb3-3, is a negative regulator of RAS activation.

Authors:  Caroline Seiler; Amy K Stainthorp; Sophie Ketchen; Christopher M Jones; Kate Marks; Philip Quirke; John E Ladbury
Journal:  Commun Biol       Date:  2022-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.